Should biologics for psoriasis be interrupted in the era of COVID-19?

被引：130

作者：

Lebwohl, Mark ^{[1
]}

Rivera-Oyola, Ryan ^{[1
]}

Murrell, Dedee F. ^{[2
]}

机构：

[1] Mt Sinai Hosp, Icahn Sch Med, New York, NY 10029 USA

[2] Univ New South Wales, St George Hosp, Sydney, NSW, Australia

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2020年 / 82卷 / 05期

关键词：

RETREATMENT; MODERATE;

D O I：

10.1016/j.jaad.2020.03.031

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

[No abstract available]

引用

页码：1217 / 1218

页数：2

共 4 条

[1] Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis [J].

Blauvelt, A. ;

Papp, K. A. ;

Sofen, H. ;

Augustin, M. ;

Yosipovitch, G. ;

Katoh, N. ;

Mrowietz, U. ;

Ohtsuki, M. ;

Poulin, Y. ;

Shrom, D. ;

Burge, R. ;

See, K. ;

Mallbris, L. ;

Gordon, K. B. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (06) :1004-1013

[2]

Gee Katrina, 2009, Inflammation & Allergy Drug Targets, V8, P40

[3] Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept [J].

Ortonne, J. -P. ;

Taieb, A. ;

Ormerod, A. D. ;

Robertson, D. ;

Foehl, J. ;

Pedersen, R. ;

Molta, C. ;

Freundlich, B. .

BRITISH JOURNAL OF DERMATOLOGY, 2009, 161 (05) :1190-1195

[4] Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension [J].

Reich, K. ;

Ortonne, J. -P. ;

Gottlieb, A. B. ;

Terpstra, I. J. ;

Coteur, G. ;

Tasset, C. ;

Mease, P. .

BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 (01) :180-190

← 1 →